Pluristem Therapeutics develops placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries and hematologic conditions. Co.'s product candidates include: Placenta expanded (PLX)-peripheral arterial disease, which is used in recovery following surgery for hip fracture, in Acute Respiratory Distress Syndrome associated with COVID-19 and Intermittent Claudication, and used in for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease; and PLX-R18, which is used in incomplete hematopoietic recovery following hematopoietic cell transplantation and Acute Radiation Syndrome following or before exposure to massive radiation. We show 46 historical shares outstanding datapoints in our PSTI shares outstanding history coverage, used to compute PSTI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PSTI market cap history over the course of time is important for investors
interested in comparing PSTI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PSTI versus a peer is one thing; comparing
PSTI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PSTI can fluctuate over the course of history.
With this page we aim to empower investors researching PSTI by allowing them to research the PSTI market cap history. |
Free PSTI Email Alerts:
Video: The Importance of Market Cap
